Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Официальное название

A Phase 2b/Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Обзор

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

Подробное описание

All eligible participants will undergo subcutaneous administrations of lunsekimig or matching placebo during a 48-weeks treatment period

Вмешательства

• Препарат Lunsekimig
  Pharmaceutical form: solution for injection in prefilled syringe. Route of administration: Subcutaneous injection
• Препарат Placebo
  Pharmaceutical form: solution for injection. Route of administration: Subcutaneous injection

Первичные конечные точки

• Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations [Срок оценки: From Baseline up to 48 weeks]

Вторичные конечные точки (12)

• Change from baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1) [Срок оценки: From Baseline up to 48 weeks]
• Change from baseline in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1) [Срок оценки: From Baseline up to 48 weeks]
• Change from baseline in the SGRQ-C total score [Срок оценки: From Baseline up to 48 weeks]
• SGRQ responder defined as an improvement of ≥4 points in the SGRQ-C total score [Срок оценки: From Baseline up to 48 weeks]
• Change from baseline in the Chronic airways assessment Test (CAAT) score [Срок оценки: From Baseline up to 48 weeks]
• CAAT responder defined as an improvement of ≥2 points in the CAAT total score [Срок оценки: From Baseline up to 48 weeks]
• Change from baseline in the E-RS:COPD total score [Срок оценки: From Baseline up to 48 weeks]
• E-RS:COPD responder defined as an improvement of ≥2 points in the E-RS:COPD total score [Срок оценки: From Baseline up to 48 weeks]
• Annualized rate of severe COPD exacerbations [Срок оценки: From Baseline up to 48 weeks]
• Time to first moderate or severe COPD exacerbation [Срок оценки: From Baseline up to 48 weeks]
• Time to first severe COPD exacerbation [Срок оценки: From Baseline up to 48 weeks]
• Incidence of participants with TEAEs, including AESIs, and SAEs [Срок оценки: From Baseline up to 56 weeks]

Критерии участия

Критерии включения

• Between 40 to 80 years of age
• Physician diagnosed chronic obstructive pulmonary disease (COPD) ≥1 year
• Post-bronchodilator forced expiratory volume in 1 second (post-BD FEV1) ≥ 20% and ≤ 70% of predicted value and FEV1/FVC (forced expiratory volume in 1 second /forced vital capacity) <0.70
• Former or current smokers ≥10 pack-years
• Chronic Airways Assessment Test (CAAT) ≥10
• ≥2 moderate or ≥1 severe COPD exacerbations in the prior year
• Triple (ICS+LABA+LAMA) COPD therapy ≥12 consecutive weeks
• EOS (blood eosinophil count) ≥ 150 cells/μL
• 18.0 ≤ Body Mass Index ≤ 40.0 kg/m2

Критерии исключения

Participants are excluded from the study if any of the following criteria apply:

• Asthma, including pediatric asthma, or asthma-COPD overlap syndrome (ACOS)
• Significant pulmonary disease other than COPD
• Long-term oxygen therapy >4.0 L/min or requirement of >2.0 L/min to maintain oxygen saturation >88% at rest
• Unstable disorder that can impact participants safety or study outcomes
• Active or incompletely treated tuberculosis
• Current or past malignancies
• Concomitant therapies:

• long-term macrolides or phosphodiesterase Type 3 (PDE-3) or PDE-4 inhibitors unless on stable therapy for > 6 months
• any biologic therapy or systemic immunosuppressant within 4 months or 5 half-lives prior to Screening

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Китай · 72 центра

Список центров уточняется — проверьте первичный протокол.

США · 54 центра

• University of Alabama at Birmingham- Site Number : 8400003 — Birmingham
• Tucson Clinical Research Institute- Site Number : 8400006 — Tucson
• Inglewood Clinical- Site Number : 8400074 — Inglewood
• Ark Clinical Research- Site Number : 8400113 — Long Beach
• Alliance Clinical - West Hills- Site Number : 8400067 — Los Angeles
• California Medical Research Associates - Northridge- Site Number : 8400089 — Northridge
• Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8400005 — Boulder
• Critical Care Pulmonary & Sleep Associates- Site Number : 8400081 — Lakewood
• … и ещё 46 центров

Аргентина · 12 центров

• Investigational Site Number : 0320011 — Berazategui
• Investigational Site Number : 0320004 — Buenos Aires
• Investigational Site Number : 0320002 — Buenos Aires
• Investigational Site Number : 0320005 — Buenos Aires
• Investigational Site Number : 0320006 — Buenos Aires
• Investigational Site Number : 0320001 — Buenos Aires
• Investigational Site Number : 0320012 — Buenos Aires
• Investigational Site Number : 0320003 — Buenos Aires
• … и ещё 4 центра

Канада · 11 центров

• Investigational Site Number : 1240051 — Kelowna
• Investigational Site Number : 1240052 — West Vancouver
• Investigational Site Number : 1240041 — Windsor
• … и ещё 8 центров

ЮАР · 11 центров

Список центров уточняется — проверьте первичный протокол.

Великобритания · 10 центров

Список центров уточняется — проверьте первичный протокол.

Тайвань · 8 центров

Список центров уточняется — проверьте первичный протокол.

Чили · 7 центров

Список центров уточняется — проверьте первичный протокол.

South Korea · 7 центров

Список центров уточняется — проверьте первичный протокол.

Австралия · 6 центров

• Investigational Site Number : 0360008 — Tiwi
• Investigational Site Number : 0360006 — South Brisbane
• Investigational Site Number : 0360004 — Townsville
• Investigational Site Number : 0360002 — Traralgon
• Investigational Site Number : 0360001 — Osborne Park
• Investigational Site Number : 5540004 — Dunedin

Малайзия · 6 центров

Список центров уточняется — проверьте первичный протокол.

Бразилия · 5 центров

• Universidade Federal de Goias- Site Number : 0760002 — Goiânia
• Santa Casa de Misericordia de Belo Horizonte- Site Number : 0760004 — Belo Horizonte
• WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760003 — Porto Alegre
• Centro Multidisciplinar de Estudos Clínicos- Site Number : 0760001 — São Bernardo do Campo
• IBCC - Núcleo de Pesquisa e Ensino- Site Number : 0760005 — São Paulo

Новая Зеландия · 3 центра

Список центров уточняется — проверьте первичный протокол.

Сингапур · 1 центр

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07190222 · EFC18244 · 2024-518213-25-00 · U1111-1308-9980

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗